PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence
Main Author: | |
---|---|
Publication Date: | 2016 |
Other Authors: | , , , , , |
Format: | Article |
Language: | por eng |
Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
Download full: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056 |
Summary: | Introduction: In prostate cancer, after therapy with curative intent, biochemical recurrence frequently occurs. The purpose of this study was to evaluate the impact of PET/CT with 18F-fluorocholine in restaging these patients and in their orientation, and to analyze the effect of the risk stratification, the values of PSA and the hormone suppression therapy, in the technique sensitivity. Material and Methods: Retrospective analysis of 107 patients with prostate carcinoma in biochemical recurrence who underwent PET/CT with 18F-fluorocholine in our hospital, between December 2009 and May 2014. Results: The overall sensitivity was 63.2% and 80.0% when PSA > 2 ng/mL. It was possible to identify distant disease in 28% of the patients. The sensitivity increased from 40.0%, in patients with low and intermediate risk, to 55.2% in high-risk patients. Without hormonal suppression therapy, the sensitivity was 61.8%, while in the group under this therapy, was 67.7%. Discussion: PET/CT with 18F-fluorocholine provided important information even in patients with low levels of PSA, however, with significantly increased sensitivity in patients with PSA > 2 ng/mL. Sensitivity was higher in high-risk patients compared with low and intermediate risk patients, however, without a statistically significant difference. The hormone suppression therapy does not appear to influence uptake of 18F-fluorocholine in patients resistant to castration. Conclusions: In this study, PET/CT with 18F-Fluorocholine showed good results in restaging patients with prostate cancer biochemical recurrence, distinguishing between loco regional and systemic disease, information with important consequences in defining the therapeutic strategy. |
id |
RCAP_094732fd12aea70ae6b8aeef63e4c1e8 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/7056 |
network_acronym_str |
RCAP |
network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository_id_str |
https://opendoar.ac.uk/repository/7160 |
spelling |
PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical RecurrencePET/CT com Fluorocolina-F18 em Doentes com Carcinoma da Próstata em Recidiva BioquímicaFluorocholinePositron-Emission TomographyProstatic NeoplasmsRadiopharmaceuticals.FluorocolinaNeoplasias da PróstataRadiofármacosTomografia por Emissão de Positrões.Introduction: In prostate cancer, after therapy with curative intent, biochemical recurrence frequently occurs. The purpose of this study was to evaluate the impact of PET/CT with 18F-fluorocholine in restaging these patients and in their orientation, and to analyze the effect of the risk stratification, the values of PSA and the hormone suppression therapy, in the technique sensitivity. Material and Methods: Retrospective analysis of 107 patients with prostate carcinoma in biochemical recurrence who underwent PET/CT with 18F-fluorocholine in our hospital, between December 2009 and May 2014. Results: The overall sensitivity was 63.2% and 80.0% when PSA > 2 ng/mL. It was possible to identify distant disease in 28% of the patients. The sensitivity increased from 40.0%, in patients with low and intermediate risk, to 55.2% in high-risk patients. Without hormonal suppression therapy, the sensitivity was 61.8%, while in the group under this therapy, was 67.7%. Discussion: PET/CT with 18F-fluorocholine provided important information even in patients with low levels of PSA, however, with significantly increased sensitivity in patients with PSA > 2 ng/mL. Sensitivity was higher in high-risk patients compared with low and intermediate risk patients, however, without a statistically significant difference. The hormone suppression therapy does not appear to influence uptake of 18F-fluorocholine in patients resistant to castration. Conclusions: In this study, PET/CT with 18F-Fluorocholine showed good results in restaging patients with prostate cancer biochemical recurrence, distinguishing between loco regional and systemic disease, information with important consequences in defining the therapeutic strategy.Introdução: No carcinoma da próstata, é frequente, após terapêutica com intuito curativo, ocorrer recidiva bioquímica. O objectivo deste trabalho foi avaliar o impacto da PET/CT com fluorocolina-F18 no restadiamento e orientação destes doentes e analisar a influência, da estratificação de risco, dos valores do PSA e da terapêutica de supressão hormonal, na sensibilidade da técnica. Material e Métodos: Análise retrospectiva de 107 doentes com carcinoma da próstata em recidiva bioquímica que realizaram PET/CT com fluorocolina-F18 no nosso hospital, entre dezembro de 2009 e maio de 2014. Resultados: A sensibilidade global foi de 63,2% sendo 80,0% quando PSA > 2 ng/mL. Foi possível identificar doença à distância em 28% dos doentes. A sensibilidade aumentou de 40,0% em doentes de risco baixo e intermédio para 55,2% em doentes de alto risco. Sem terapêutica de supressão hormonal, a sensibilidade foi de 61,8% enquanto no grupo sob essa terapêutica, foi de 67,7%. Discussão: A PET/CT com fluorocolina-F18 forneceu informações relevantes, mesmo em doentes com baixos valores do PSA, contudo, com incremento significativo da sensibilidade nos doentes com PSA >2 ng/mL. A sensibilidade foi superior nos doentes de alto risco comparativamente com os de risco baixo e intermédio, contudo, sem uma diferença estatisticamente significativa. A terapêutica de supressão hormonal parece não influenciar a captação de Fluorocolina-F18 nos doentes resistentes à castração. Conclusões: Neste estudo, a PET/CT com fluorocolina-F18 apresentou bons resultados no restadiamento de doentes com carcinoma da próstata em recidiva bioquímica, distinguindo entre doença loco-regional e sistémica, informação com importantes consequências na definição da estratégia terapêutica.Ordem dos Médicos2016-03-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfimage/jpegimage/pngimage/pngimage/pngimage/pngimage/pngimage/pnghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056oai:ojs.www.actamedicaportuguesa.com:article/7056Acta Médica Portuguesa; Vol. 29 No. 3 (2016): March; 182-192Acta Médica Portuguesa; Vol. 29 N.º 3 (2016): Março; 182-1921646-07580870-399Xreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAPporenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/4617https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/4777https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/7943https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8098https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8220https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8221https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8222https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8223https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8224https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8225Direitos de Autor (c) 2016 Copyright © Ordem dos Médicosinfo:eu-repo/semantics/openAccessLapa, PaulaSilva, RodolfoSaraiva, TiagoFigueiredo, ArnaldoFerreira, RuiCosta, GracindaLima, João Pedroso2022-12-20T11:05:05Zoai:ojs.www.actamedicaportuguesa.com:article/7056Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T10:40:46.217036Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
dc.title.none.fl_str_mv |
PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence PET/CT com Fluorocolina-F18 em Doentes com Carcinoma da Próstata em Recidiva Bioquímica |
title |
PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence |
spellingShingle |
PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence Lapa, Paula Fluorocholine Positron-Emission Tomography Prostatic Neoplasms Radiopharmaceuticals. Fluorocolina Neoplasias da Próstata Radiofármacos Tomografia por Emissão de Positrões. |
title_short |
PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence |
title_full |
PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence |
title_fullStr |
PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence |
title_full_unstemmed |
PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence |
title_sort |
PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence |
author |
Lapa, Paula |
author_facet |
Lapa, Paula Silva, Rodolfo Saraiva, Tiago Figueiredo, Arnaldo Ferreira, Rui Costa, Gracinda Lima, João Pedroso |
author_role |
author |
author2 |
Silva, Rodolfo Saraiva, Tiago Figueiredo, Arnaldo Ferreira, Rui Costa, Gracinda Lima, João Pedroso |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Lapa, Paula Silva, Rodolfo Saraiva, Tiago Figueiredo, Arnaldo Ferreira, Rui Costa, Gracinda Lima, João Pedroso |
dc.subject.por.fl_str_mv |
Fluorocholine Positron-Emission Tomography Prostatic Neoplasms Radiopharmaceuticals. Fluorocolina Neoplasias da Próstata Radiofármacos Tomografia por Emissão de Positrões. |
topic |
Fluorocholine Positron-Emission Tomography Prostatic Neoplasms Radiopharmaceuticals. Fluorocolina Neoplasias da Próstata Radiofármacos Tomografia por Emissão de Positrões. |
description |
Introduction: In prostate cancer, after therapy with curative intent, biochemical recurrence frequently occurs. The purpose of this study was to evaluate the impact of PET/CT with 18F-fluorocholine in restaging these patients and in their orientation, and to analyze the effect of the risk stratification, the values of PSA and the hormone suppression therapy, in the technique sensitivity. Material and Methods: Retrospective analysis of 107 patients with prostate carcinoma in biochemical recurrence who underwent PET/CT with 18F-fluorocholine in our hospital, between December 2009 and May 2014. Results: The overall sensitivity was 63.2% and 80.0% when PSA > 2 ng/mL. It was possible to identify distant disease in 28% of the patients. The sensitivity increased from 40.0%, in patients with low and intermediate risk, to 55.2% in high-risk patients. Without hormonal suppression therapy, the sensitivity was 61.8%, while in the group under this therapy, was 67.7%. Discussion: PET/CT with 18F-fluorocholine provided important information even in patients with low levels of PSA, however, with significantly increased sensitivity in patients with PSA > 2 ng/mL. Sensitivity was higher in high-risk patients compared with low and intermediate risk patients, however, without a statistically significant difference. The hormone suppression therapy does not appear to influence uptake of 18F-fluorocholine in patients resistant to castration. Conclusions: In this study, PET/CT with 18F-Fluorocholine showed good results in restaging patients with prostate cancer biochemical recurrence, distinguishing between loco regional and systemic disease, information with important consequences in defining the therapeutic strategy. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-03-31 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056 oai:ojs.www.actamedicaportuguesa.com:article/7056 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/7056 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/4617 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/4777 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/7943 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8098 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8220 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8221 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8222 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8223 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8224 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8225 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2016 Copyright © Ordem dos Médicos info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2016 Copyright © Ordem dos Médicos |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf image/jpeg image/png image/png image/png image/png image/png image/png |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 29 No. 3 (2016): March; 182-192 Acta Médica Portuguesa; Vol. 29 N.º 3 (2016): Março; 182-192 1646-0758 0870-399X reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
repository.mail.fl_str_mv |
info@rcaap.pt |
_version_ |
1833591117055000576 |